Movers: Apple, AstraZeneca, Nio, Rivian, Tesla, Xpeng

  • Scott Peters
  • U.S.A. New York City
  • Jul 3, 2023
  • AstraZeneca declined after preliminary results for a phase three trial of a lung cancer treatment lagged expectations. Tesla reported record second quarter production and deliveries. Rivian Automotive reiterated annual production target.

    The S&P 500 index traded nearly unchanged at 4,452.02 and the Nasdaq Composite edged higher 0.3% to 13,830.38..  

    The S&P 500 index advanced 5.2% in June and jumped 7% in the second quarter, the third quarterly gain in a row and jumped 15.9% in the first half. 

    The Nasdaq Composite increased 5.1% in June, advanced 11.2% in the second quarter and soared nearly 31.7% in the first half of 2023. 

    Tesla Inc jumped 8.5% to $283.86 after the maker of electric vehicles reported deliveries and production of electric vehicles in the second quarter. 

    Tesla shares are up 156% in the year sofar. 

    The company produced 479,700 vehicles and delivered 466,140 in the second quarter. 

    The company produced 258,500 vehicles and delivered 254,695 vehicles in the quarter a year ago. 

    Sales in the latest quarter were supported by as much as $10,000 incentives and $7,500 federal tax credit under the U.S. Inflation Reduction Act.  

    Rivian Automotive Inc jumped 14.8% to $19.14 after the maker of pickups and SUVs said it delivered 12,640 vehicles in the second quarter, an increase of 59% from the previous quarter. 

    The company reiterated its annual production target of 50,000.  

    Chinese electric vehicle makers trading in New York advanced after Tesla reported higher-than-expected quarterly production and deliveries. 

    Xpeng Inc jumped 7% and Nio Inc gained 5%. 

    Apple Inc edged down 0.6% to $192.94 after a report suggested that the company is looking to scale back production of Vision Pro headsets.  

    AstraZeneca Plc declined 5.6% to 10,638.0 pence in London and fell 8.9% to $65.19 in New York trading after the latest results from a broad study for a cancer drug lagged expectations. 

    The company announced disappointing preliminary results for a phase three trial of experimental lung cancer treatment drug. 

Annual Returns

Company Ticker 2024 2023 2022
Tesla Inc TSLA -6% 48% -84%
XPeng Inc. XPEV -44% 39% -79%
Apple Inc AAPL 16% 43% -24%
Rivian Automotive Inc. RIVN -30% -8% -75%
Astrazeneca PLC AZN 17% -3% 19%
NIO Inc. NIO -51% -27% -61%